propranolol has been researched along with Hemostatic Disorders in 1 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
Hemostatic Disorders: Pathological processes involving the integrity of blood circulation. Hemostasis depends on the integrity of BLOOD VESSELS, blood fluidity, and BLOOD COAGULATION. Majority of the hemostatic disorders are caused by disruption of the normal interaction between the VASCULAR ENDOTHELIUM, the plasma proteins (including BLOOD COAGULATION FACTORS), and PLATELETS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Peuvrel, L | 1 |
| Bregeon, B | 1 |
| Saint-Jean, M | 1 |
| Quéreux, G | 1 |
| Frénard, C | 1 |
| Khammari, A | 1 |
| Wdowik, A | 1 |
| Dréno, B | 1 |
1 other study available for propranolol and Hemostatic Disorders
| Article | Year |
|---|---|
First case of trastuzumab emtansine-associated hemorrhagic telangiectasias treated with propranolol.
Topics: Ado-Trastuzumab Emtansine; Adrenergic beta-Antagonists; Antineoplastic Agents, Immunological; Female | 2019 |